JP2024518735A5 - - Google Patents
Info
- Publication number
- JP2024518735A5 JP2024518735A5 JP2023564485A JP2023564485A JP2024518735A5 JP 2024518735 A5 JP2024518735 A5 JP 2024518735A5 JP 2023564485 A JP2023564485 A JP 2023564485A JP 2023564485 A JP2023564485 A JP 2023564485A JP 2024518735 A5 JP2024518735 A5 JP 2024518735A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025153759A JP2026012677A (ja) | 2021-04-23 | 2025-09-17 | 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178745P | 2021-04-23 | 2021-04-23 | |
| US63/178,745 | 2021-04-23 | ||
| US202163221986P | 2021-07-15 | 2021-07-15 | |
| US63/221,986 | 2021-07-15 | ||
| US202163270091P | 2021-10-21 | 2021-10-21 | |
| US63/270,091 | 2021-10-21 | ||
| PCT/EP2022/060670 WO2022223771A1 (en) | 2021-04-23 | 2022-04-22 | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025153759A Division JP2026012677A (ja) | 2021-04-23 | 2025-09-17 | 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2024518735A JP2024518735A (ja) | 2024-05-02 |
| JP2024518735A5 true JP2024518735A5 (https=) | 2024-11-12 |
| JPWO2022223771A5 JPWO2022223771A5 (https=) | 2024-11-12 |
| JP7746407B2 JP7746407B2 (ja) | 2025-09-30 |
Family
ID=81750638
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564485A Active JP7746407B2 (ja) | 2021-04-23 | 2022-04-22 | 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療 |
| JP2025153759A Pending JP2026012677A (ja) | 2021-04-23 | 2025-09-17 | 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025153759A Pending JP2026012677A (ja) | 2021-04-23 | 2025-09-17 | 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20220348669A1 (https=) |
| EP (2) | EP4595996A3 (https=) |
| JP (2) | JP7746407B2 (https=) |
| KR (1) | KR20240001704A (https=) |
| AU (1) | AU2022260544A1 (https=) |
| BR (1) | BR112023021514A2 (https=) |
| CA (1) | CA3216395A1 (https=) |
| DK (1) | DK4192882T3 (https=) |
| ES (1) | ES3021882T3 (https=) |
| FI (1) | FI4192882T3 (https=) |
| HU (1) | HUE070524T2 (https=) |
| IL (1) | IL307751B2 (https=) |
| PL (1) | PL4192882T3 (https=) |
| PT (1) | PT4192882T (https=) |
| TW (1) | TW202308691A (https=) |
| WO (1) | WO2022223771A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231255T1 (hr) | 2021-04-23 | 2024-02-02 | Astrazeneca Ab | Režim doziranja anti-ifnar1 za potkožnu injekciju |
| CN113278071B (zh) * | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| GB202402824D0 (en) * | 2024-02-28 | 2024-04-10 | Astrazeneca Ab | Treatment of chronic kidney disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035082T2 (en) | 2004-06-21 | 2018-05-02 | Squibb & Sons Llc | Interferon alpha receptor 1 antibodies and their use |
| HRP20160855T1 (hr) | 2008-02-08 | 2016-09-23 | Medimmune, Llc | Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda |
| US20120251546A1 (en) | 2009-09-03 | 2012-10-04 | Medimmune Llc | Type 1 inteferon diagnostic |
| PH12016502073B1 (en) * | 2010-11-17 | 2024-04-05 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| AU2013274389A1 (en) * | 2012-06-13 | 2015-01-22 | Astrazeneca Ab | Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies |
| CA2995222C (en) | 2015-08-19 | 2021-07-13 | Medimmune, Llc | Stable anti-ifnar1 formulation |
| WO2017186928A1 (en) * | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| CN106243226B (zh) | 2016-08-05 | 2019-02-12 | 北京智仁美博生物科技有限公司 | 抗人ifnar1的抗体及其用途 |
| HRP20231255T1 (hr) * | 2021-04-23 | 2024-02-02 | Astrazeneca Ab | Režim doziranja anti-ifnar1 za potkožnu injekciju |
| CN113278070B (zh) | 2021-04-25 | 2022-06-14 | 福州迈新生物技术开发有限公司 | 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用 |
| CN113527490B (zh) * | 2021-07-13 | 2022-03-01 | 江苏荃信生物医药股份有限公司 | 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法 |
| CN113621063A (zh) * | 2021-08-02 | 2021-11-09 | 江苏荃信生物医药有限公司 | 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法 |
-
2022
- 2022-04-22 PT PT227247129T patent/PT4192882T/pt unknown
- 2022-04-22 AU AU2022260544A patent/AU2022260544A1/en active Pending
- 2022-04-22 US US17/660,340 patent/US20220348669A1/en active Pending
- 2022-04-22 KR KR1020237040114A patent/KR20240001704A/ko active Pending
- 2022-04-22 ES ES22724712T patent/ES3021882T3/es active Active
- 2022-04-22 TW TW111115513A patent/TW202308691A/zh unknown
- 2022-04-22 FI FIEP22724712.9T patent/FI4192882T3/fi active
- 2022-04-22 DK DK22724712.9T patent/DK4192882T3/da active
- 2022-04-22 PL PL22724712.9T patent/PL4192882T3/pl unknown
- 2022-04-22 CA CA3216395A patent/CA3216395A1/en active Pending
- 2022-04-22 EP EP25158131.0A patent/EP4595996A3/en active Pending
- 2022-04-22 WO PCT/EP2022/060670 patent/WO2022223771A1/en not_active Ceased
- 2022-04-22 IL IL307751A patent/IL307751B2/en unknown
- 2022-04-22 HU HUE22724712A patent/HUE070524T2/hu unknown
- 2022-04-22 JP JP2023564485A patent/JP7746407B2/ja active Active
- 2022-04-22 US US18/556,733 patent/US20250002590A1/en active Pending
- 2022-04-22 EP EP22724712.9A patent/EP4192882B1/en active Active
- 2022-04-22 BR BR112023021514A patent/BR112023021514A2/pt unknown
-
2025
- 2025-09-17 JP JP2025153759A patent/JP2026012677A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025003552A1 (es) | Autoinyector y métodos de uso relacionados. | |
| JP2024518735A5 (https=) | ||
| BR102022025291A2 (https=) | ||
| CL2025003908A1 (es) | Composiciones halogenadas libres de metales pesados | |
| CL2025003924A1 (es) | Sistemas y métodos para explosión comercial. | |
| BR102023014872A2 (https=) | ||
| BR102023010976A2 (https=) | ||
| BR102023009641A2 (https=) | ||
| BR102023008688A2 (https=) | ||
| BR102023007252A2 (https=) | ||
| BR102023005164A2 (https=) | ||
| BR102023001877A2 (https=) | ||
| BR102023000289A2 (https=) | ||
| BR102022026909A2 (https=) | ||
| BR102022023461A2 (https=) | ||
| BR202022009269U2 (https=) | ||
| BR202022005961U2 (https=) | ||
| BR202022001779U2 (https=) | ||
| BR202022000931U2 (https=) | ||
| BY13137U (https=) | ||
| BY13167U (https=) | ||
| BY13140U (https=) | ||
| CN307044816S (https=) | ||
| CN307045726S (https=) | ||
| CN307045916S (https=) |